SP-8356, a (1S)-(-)-Verbenone Derivative, Inhibits the Growth and Motility of Liver Cancer Cells by Regulating NF-κB and ERK Signaling |
Kim, Dong Hwi
(Department of Biomedical Science, Korea University College of Medicine)
Yong, Hyo Jeong (Department of Biomedical Science, Korea University College of Medicine) Mander, Sunam (Department of Biomedical Science, Korea University College of Medicine) Nguyen, Huong Thi (Department of Biomedical Science, Korea University College of Medicine) Nguyen, Lan Phuong (Department of Biomedical Science, Korea University College of Medicine) Park, Hee-Kyung (Department of Biomedical Science, Korea University College of Medicine) Cha, Hyo Kyeong (Department of Biomedical Science, Korea University College of Medicine) Kim, Won-Ki (Department of Biomedical Science, Korea University College of Medicine) Hwang, Jong-Ik (Department of Biomedical Science, Korea University College of Medicine) |
1 | Arii, S., Mise, M., Harada, T., Furutani, M., Ishigami, S., Niwano, M., Mizumoto, M., Fukumoto, M. and Imamura, M. (1996) Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 24, 316-322. DOI |
2 | Bruix, J. and Sherman, M.; American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53, 1020-1022. DOI |
3 | Chaffer, C. L. and Weinberg, R. A. (2011) A perspective on cancer cell metastasis. Science 331, 1559. DOI |
4 | Chambard, J. C., Lefloch, R., Pouyssegur, J. and Lenormand, P. (2007) ERK implication in cell cycle regulation. Biochim. Biophys. Acta 1773, 1299-1310. DOI |
5 | Chan, C. F., Yau, T. O., Jin, D. Y., Wong, C. M., Fan, S. T. and Ng, I. O. (2004) Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma. Clin. Cancer Res. 10, 4140-4149. DOI |
6 | Chen, L., Li, M., Li, Q., Wang, C. J. and Xie, S. Q. (2013) DKK1 promotes hepatocellular carcinoma cell migration and invasion through β-catenin/MMP7 signaling pathway. Mol. Cancer 12, 157. DOI |
7 | Choi, I. Y., Lim, J. H., Hwang, S., Lee, J. C., Cho, G. S. and Kim, W. K. (2010) Anti-ischemic and anti-inflammatory activity of (S)-cisverbenol. Free. Radic. Res. 44, 541-551. DOI |
8 | El-Serag, H. B. and Rudolph, K. L. (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-2576. DOI |
9 | Flores, K. and Seger, R. (2013) Stimulated nuclear import by β-like importins. F1000Prime Rep. 5, 41. DOI |
10 | Hoesel, B. and Schmid, J. A. (2013) The complexity of NF-κB signaling in inflammation and cancer. Mol. Cancer 12, 86. DOI |
11 | Huber, M. A., Azoitei, N., Baumann, B., Grbnert, S., Sommer, A., Pehamberger, H., Kraut, N., Beug, H. and Wirth, T. (2004) NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J. Clin. Invest. 114, 569-581. DOI |
12 | Je, Y., Schutz, F. A. B. and Choueiri, T. K. (2009) Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol. 10, 967-974. DOI |
13 | Ju, C., Song, S., Hwang, S., Kim, C., Kim, M., Gu, J., Oh, Y. K., Lee, K., Kwon, J., Lee, K., Kim, W. K. and Choi, Y. (2013) Discovery of novel (1S)-(-)-verbenone derivatives with anti-oxidant and antiischemic effects. Bioorg. Med. Chem. Lett. 23, 5421-5425. DOI |
14 | Naugler, W. E. and Karin, M. (2008) NF-κB and cancer-identifying targets and mechanisms. Curr. Opin. Genet. Dev. 18, 19-26. DOI |
15 | Min, C., Eddy, S. F., Sherr, D. H. and Sonenshein, G. E. (2008) NF-kappaB and epithelial to mesenchymal transition of cancer. J. Cell. Biochem. 104, 733-744. DOI |
16 | Min, L., He, B. and Hui, L. (2011) Mitogen-activated protein kinases in hepatocellular carcinoma development. Semin. Cancer Biol. 21, 10-20. DOI |
17 | Nakagawa, H. and Maeda, S. (2012) Inflammation- and stress-related signaling pathways in hepatocarcinogenesis. World J. Gastroenterol. 18, 4071-4081. DOI |
18 | Okusaka, T., Okada, S., Ishii, H., Nose, H., Nagahama, H., Nakasuka, H., Ikeda, K. and Yoshimori, M. (1997) Prognosis of hepatocellular carcinoma patients with extrahepatic metastases. Hepatogastroenterology 44, 251-257. |
19 | Kuo, C. F., Su, J. D., Chiu, C. H., Peng, C. C., Chang, C. H., Sung, T. Y., Huang, S. H., Lee, W. C. and Chyau, C. C. (2011) Anti-inflammatory effects of supercritical carbon dioxide extract and its isolated carnosic acid from Rosmarinus officinalis leaves. J. Agric. Food Chem. 59, 3674-3685. DOI |
20 | Coussens, L. M. and Werb, Z. (2002) Inflammation and cancer. Nature 420, 860-867. DOI |
21 | Li, W., Tan, D., Zenali, M. J. and Brown, R. E. (2009) Constitutive activation of nuclear factor-kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma. Int. J. Clin. Exp. Pathol. 3, 238-243. |
22 | Lin, Y., Liu, J., Huang, Y., Liu, D., Zhang, G. and Kan, H. (2017) microRNA-489 plays an anti-metastatic role in human hepatocellular carcinoma by targeting matrix metalloproteinase-7. Transl. Oncol. 10, 211-220. DOI |
23 | Tung-Ping Poon, R., Fan, S. T. and Wong, J. (2000) Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann. Surg. 232, 10-24. DOI |
24 | Singh, A. K., Kumar, R. and Pandey, A. K. (2018) Hepatocellular Carcinoma: causes, mechanism of progression and biomarkers. Curr. Chem. Genom. Transl. Med. 12, 9-26. DOI |
25 | Wu, J. M., Sheng, H., Saxena, R., Skill, N. J., Bhat-Nakshatri, P., Yu, M., Nakshatri, H. and Maluccio, M. A. (2009) NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Lett. 278, 145-155. DOI |
26 | Yao, D. F., Wu, X. H., Zhu, Y., Shi, G. S., Dong, Z. Z., Yao, D. B., Wu, W., Qiu, L. W. and Meng, X. Y. (2005) Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 4, 220-226. |
27 | Ola, M. S., Nawaz, M. and Ahsan, H. (2011) Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol. Cell. Biochem. 351, 41-58. DOI |
28 | Pahk, K., Noh, H., Joung, C., Jang, M., Song, H. Y., Kim, K. W., Han, K., Hwang, J. I., Kim, S. and Kim, W. K. (2019) A novel CD147 inhibitor, SP-8356, reduces neointimal hyperplasia and arterial stiffness in a rat model of partial carotid artery ligation. J. Transl. Med. 17, 274. DOI |
29 | Tong, R., Yang, B., Xiao, H., Peng, C., Hu, W., Weng, X., Cheng, S., Du, C., Lv, Z., Ding, C., Zhou, L., Xie, H., Wu, J. and Zheng, S. (2017) KCTD11 inhibits growth and metastasis of hepatocellular carcinoma through activating Hippo signaling. Oncotarget 8, 37717-37729. DOI |
30 | Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J. and Jemal, A. (2015) Global cancer statistics. CA Cancer J. Clin. 2012. 65, 87-108. DOI |
31 | Uchino, K., Tateishi, R., Shiina, S., Kanda, M., Masuzaki, R., Kondo, Y., Goto, T., Omata, M., Yoshida, H. and Koike, K. (2011) Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer 117, 4475-4483. DOI |
32 | Uka, K., Aikata, H., Takaki, S., Shirakawa, H., Jeong, S. C., Yamashina, K., Hiramatsu, A., Kodama, H., Takahashi, S. and Chayama, K. (2007) Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J. Gastroenterol. 13, 414-420. DOI |
33 | Ulisse, S., Baldini, E., Sorrenti, S. and D'armiento, M. (2009) The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr. Cancer Drug Targets 9, 32-71. DOI |
34 | Valastyan, S. and Weinberg, R. A. (2011) Tumor metastasis: molecular insights and evolving paradigms. Cell 147, 275-92. DOI |
35 | Wang, J., Huang, Q. and Chen, M. (2003) The role of NF-kappaB in hepatocellular carcinoma cell. Chin. Med. J. 116, 747-752. |
36 | Plotnikov, A., Zehorai, E., Procaccia, S. and Seger, R. (2011) The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim. Biophys. Acta 1813, 1619-1633. DOI |
37 | Yeh, C. B., Hsieh, M. J., Hsieh, Y. H., Chien, M. H., Chiou, H. L. and Yang, S. F. (2012) Antimetastatic effects of norcantharidin on hepatocellular carcinoma by transcriptional inhibition of MMP-9 through modulation of NF-kB activity. PLoS ONE 7, e31055. DOI |
38 | Zhu, Y. J., Zheng, B., Wang, H. Y. and Chen, L. (2017) New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol. Sin. 38, 614-622. DOI |
39 | Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E. and BenNeriah, Y. (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431, 461-466. DOI |
40 | Plotnikov, A., Flores, K., Maik-Rachline, G., Zehorai, E., Kapri-Pardes, E., Berti, D. A., Hanoch, T., Besser, M. J. and Seger, R. (2015) The nuclear translocation of ERK1/2 as an anticancer target. Nat. Commun. 6, 6685. DOI |
41 | Poddar, N., Ramlal, R., Ravulapati, S., Devlin, S. M., Gadani, S., Vidal, C. I., Cao, D., Befeler, A. S. and Lai, J. (2017) Extrahepatic metastasis of hepatocellular carcinoma arising from a hepatic adenoma without concurrent intrahepatic recurrence. Curr. Oncol. 24, e333-e336. |
42 | Ranjan, A., Iyer, S. V., Ward, C., Link, T., Diaz, F. J., Dhar, A., Tawfik, O. W., Weinman, S. A., Azuma, Y., Izumi, T. and Iwakuma, T. (2018) MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma. Oncotarget 9, 21429-21443. DOI |
43 | Saharinen, P., Eklund, L., Pulkki, K., Bono, P. and Alitalo, K. (2011) VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol. Med. 17, 347-362. DOI |
44 | Siegel, R. L., Miller, K. D. and Jemal, A. (2018) Cancer statistics, 2018. CA Cancer J. Clin. 68, 7-30. DOI |
45 | Marrero, C. R. and Marrero, J. A. (2007) Viral hepatitis and hepatocellular carcinoma. Arch. Med. Res. 38, 612-620. DOI |
46 | Liu, P., Cheng, H., Roberts, T. M. and Zhao, J. J. (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627-644. DOI |
47 | Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., De Oliveira, A. C., Santoro, A., Raoul, J. L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T. F., Galle, P. R., Seitz, J. F., Borbath, I., Haeussinger, D., Giannaris, T., Shan, M., Moscovici, M., Voliotis, D. and Bruix, J. (2008) Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390. DOI |
48 | Mander, S., Kim, D. H., Thi Nguyen, H., Yong, H. J., Pahk, K., Kim, E. Y., Lee, K., Seong, J. Y., Kim, W. K. and Hwang, J. I. (2019) SP8356, a (1S)-(-)-verbenone derivative, exerts in vitro and in vivo anti-breast cancer effects by inhibiting NF-κB signaling. Sci. Rep. 9, 6595. DOI |
![]() |